EXTENDED CYTOGENETIC FOLLOW-UP AND CLINICAL-PROGRESS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

被引：19

作者：

WHITE, AD

HOY, TG

JACOBS, A

机构：

[1] Department of Haematology, University of Wales College of Medicine, Cardiff, Heath Park

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 12卷 / 5-6期

关键词：

CYTOGENETICS; MYELODYSPLASTIC SYNDROMES; FOLLOW-UP; KARYOTYPE; MDS;

D O I：

10.3109/10428199409073781

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

198 patients with MDS were followed cytogenetically for up to 90 months. There were significant differences in survival between patients with a normal karyotype, single abnormalities (p < 0.05) and multiple abnormalities (p < 0.0001). Survival differences were also seen in each of the FAB sub-types but were only significant in RAEB/RAEB-t and CMML (p = 0.001) where a normal karyotype was associated with prolonged survival. Single and multiple abnormalities of chromosomes 7 and 8 but only multiple abnormalities of chromosome 5 were also associated with reduced survival. 126 patients were successfully investigated on more than one occasion. Karyotype evolution occurred in 15 and was associated with reduced overall survival in those patients who had previously been karyotypically normal (p < 0.05). Median survival following evolution was only 10 months. 29 patients developed leukaemia. The incidence of transformation was significantly higher in patients with multiple abnormalities than in those with a normal karyotype (p < 0.05) or single abnormalities (p < 0.05).

引用

页码：401 / 412

页数：12

共 26 条

[1]

Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnik H.R., Sultan C., Proposals for the classification of the myelodysplastic syndromes, Br. J. Haematol., 51, pp. 189-199, (1982)

[2]

May S.J., Smith S.A., Jacobs A., Williams A., Bailey-Wood R., The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification, Br. J. Haematol., 59, pp. 311-319, (1985)

[3]

Harnden D.G., Klinger H.P., An international system for cytogenetic nomenclature, Cytogenetics and Cell Genetics, (1985)

[4]

Gyger M., Infante-Rivard C., D'Angelo G., Forest L., Lussier P., Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes, Am. J. Haematol., 28, pp. 13-20, (1988)

[5]

Horiike S., Taniwaki M., Misawa S., Abe T., Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis, Cancer, 62, pp. 1129-1138, (1988)

[6]

Musilova J., Michalova K., Chromosome study of 85 patients with myelodysplastic syndrome, Cancer Genet. Cytogenet., 33, pp. 39-50, (1988)

[7]

Yunis J.J., Lobell M., Arnesen M.A., Oken M.M., Mayer M.G., Rydell R.E., Brunning R.D., Refined chromosome study helps define prognostic sub-groups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia, Br. J. Haematol., 68, pp. 189-194, (1988)

[8]

Pierre R.V., Catovsky D., Mufti G.J., Swansbury G.J., Mecucci C., Dewald G.W., Ruutu T., Van Den Berghe H., Rowley J.D., Mitelman F., Reeves B.R., Alimena G., Caison O.M., Lawler S.D., de la Chapelle A., Clinical cytogenetic correlations in myelodysplasia (preleukaemia), Cancer Genet. Cytogenet., 45, pp. 149-161, (1989)

[9]

Suciu S., Kuse R., Weh H.J., Hossfeld D.K., Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome, Cancer Genet. Cytogenet., 44, pp. 15-26, (1990)

[10]

Verhoef G., De Wolf-Peeters C., Kerim S., Van De Broeck J., Mecucci C., Van Den Berghe H., Boogaerts M., Update on the prognostic implication of morphology, histology and karyotype in primary myelodysplastic syndromes, Haematol. Pathol., 5, pp. 163-175, (1991)

← 1 2 3 →